
Supplementary information

The future is not always uniform: rethinking radiotherapy through spatial fractionation

**In the format provided by
the authors and unedited**

Supplementary Table 1. Ongoing trials testing SFRT techniques.

Technique / trial	Identifier - phase	Population	Design	Sample size (planned)	Primary endpoint
<i>LATTICE radiotherapy</i>					
Lattice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial	NCT07000162 Phase II	Large lesions, multi-site	Single-arm	N: 56	ORR
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors	NCT06416007 Phase II	Large lesions, multi-site	Single-arm	N: 37	ORR
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors	NCT07058948 Phase II	Large lesions, multi-site	Single-arm	N: 30	ORR
A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases	NCT05837767 Phase II	Large lesions, multi-site	Single-arm	N: 26	ORR
<i>Grid radiotherapy</i>					
Grid Therapy for Extremity Soft Tissue Sarcoma	NCT06073067 Phase I	Soft tissue sarcoma	Single-arm	N: 20	Safety
Palliative Spatially Fractionated (grid) Radiotherapy Using Intensity Modulated Proton Therapy	NCT05831579 Phase I	Large lesions, multi-site	Single-arm	N: 20	Safety
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors (ProGRID)	NCT05121545 Phase I	Large lesions, multi-site	Single-arm	N: 11	Safety
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC	NCT05727787 Phase I	HCC	Single-arm	N: 18	Safety

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors	NCT02333110 Phase II	Large lesions, multi-site	Single-arm	N: 50	Symptom relief
<i>PATHY</i>					
Rechallenge Using Combined Partial Tumor Irradiation and Immune Checkpoint Inhibitor-based Immunotherapy for Unresectable Lung Adenocarcinoma: a pilot study.	NTC07423169 Phase I	Unresectable, bulky lung adenocarcinomas	Single-arm	N:12	PFS
<i>Minibeam radiation therapy</i>					
Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial	NCT07062003 Phase I	skin or superficial soft tissue tumor	Single-arm	N: 60	Safety

HCC, hepatocellular carcinoma; ORR, objective response rate; PFS, progression-free survival; SFRT, spatially fractionated radiotherapy.